Effect of Molnupiravir on Biomarkers, Respiratory Interventions, and Medical Services in COVID-19 : A Randomized, Placebo-Controlled Trial코로나19의 바이오마커, 호흡기 중재 및 의료 서비스에 대한 몰누피라비르의 효과 : 무작위, 위약 대조 시험Randomized Controlled Trial Published on 2022-08-012022-09-11 Journal: Annals of internal medicine [Category] COVID19(2023년), MERS, SARS, 바이오마커, 임상, [키워드] 95% CI Analysis assigned baseline benefit C-reactive protein C-reactive protein (CRP Care change clinical benefit clinically Concentration COVID-19 CRP death discharge discharged double-blind Effect evaluated faster Hospitalization Hospitalized identify immunized improvement Improvements Inc Invasive mechanical ventilation less LLC median medical service medical services Mild mild to moderate Mild to moderate COVID-19 Moderate COVID-19 molnupiravir Older oxygen oxygen saturation participant performed Phase 3 Placebo placebo-controlled placebo-treated participant placebo-treated participants potential clinical benefit progression randomization Randomized Randomly receiving reduction in Relative risk respiratory respiratory intervention respiratory interventions risk risk factor Risk factors risk reduction SARS-CoV-2 secondary service severe disease Sharp subsidiary therapy Trial [DOI] 10.7326/M22-0729 PMC 바로가기 [Article Type] Randomized Controlled Trial
Vitamin D deficiency predicts 30-day hospital mortality of adults with COVID-19Short communication Published on 2022-08-012022-10-05 Journal: Clinical nutrition ESPEN [Category] 유전자 메커니즘, [키워드] 30-Day mortality addition age chemiluminescence immunoassay conducted confounders covariate COVID-19 Cox regression deficiency diagnosis of COVID-19 disease severity evaluate hospital Hospitalization males Mortality mortality risk outcomes Patient plasma polymerase chain predict qPCR remained Result retrospective cohort study SARS-CoV-2 serum Sex shown symptom onset symptomatic two group Vitamin D vitamin D deficiency was performed with COVID-19 [DOI] 10.1016/j.clnesp.2022.05.027 [Article Type] Short communication
People’s perspectives about COVID-19 vaccination certificate: Findings from a representative Italian sampleResearch article Published on 2022-08-012022-10-05 Journal: Vaccine [Category] 변종, [키워드] Affect asked contribute country Coverage COVID-19 COVID-19 public policy COVID-19 vaccination COVID-19 vaccination certificate early phase events Factor favor finding form Health Hospitalization Increases individual individuals Italian Italian population Italy Judgment and decision-making Medical expenses pandemic participant Perspective predicted Result Risk perception Support tested the vaccine vaccination Vaccine Vaccine hesitancy [DOI] 10.1016/j.vaccine.2022.08.016 [Article Type] Research article
Remdesivir treatment in hospitalized patients affected by COVID-19 pneumonia: A case-control studyCOVID-19 폐렴에 감염된 입원 환자의 렘데시비르 치료: 사례-대조군 연구Observational Study Published on 2022-08-012022-10-30 Journal: Journal of medical virology [Category] COVID19(2023년), SARS, 임상, 치료제, [키워드] Admission adverse event adverse events affected Analysis analyzed Antiviral antiviral therapy Antiviral treatment baseline characteristics case-control study Clinical outcome clinical outcomes control group coronavirus disease Coronavirus disease 2019 COVID-19 Efficacy Hospitalization hospitalized patient hospitalized patients ICU ICU admission in vitro activity intensive care intensive care unit lower mortality mortality rate Multivariate analysis observational study Odds ratio patients treated Remdesivir reported retrospective risk SARS-CoV-2 severe coronavirus disease significantly lower subject supportive therapies survival survival analysis treated Treatment two groups viruses with COVID-19 [DOI] 10.1002/jmv.27768 PMC 바로가기 [Article Type] Observational Study
The comparative effectiveness of COVID-19 monoclonal antibodies: A learning health system randomized clinical trialRandomized Controlled Trial Published on 2022-08-012022-10-05 Journal: Contemporary clinical trials [Category] COVID19(2023년), SARS, 임상, 진단, [키워드] 95% CI adjusted odds ratio age Analysis antibody authorization Bayesian COVID-19 criteria death decrease defined Effectiveness Emergency enrolled equivalence funding Government Health health system Hospitalization inferiority IQR Local mAb median Mild moderate Moderate COVID-19 monoclonal neutralize Odds ratio outcome Patient Placebo Platform trial posterior probability Probability provided random randomized clinical trial Registered relative reported SARS-CoV-2 Sex statistical Treatment Trial [DOI] 10.1016/j.cct.2022.106822 PMC 바로가기 [Article Type] Randomized Controlled Trial
Amubarvimab/Romlusevimab: First ApprovalArticle Published on 2022-08-012022-11-15 Journal: Drugs [Category] SARS, 진단, [키워드] acute respiratory syndrome approval approved authorization China Combination coronavirus coronavirus disease COVID-19 COVID-19 in patient death Emergency high risk Hospitalization human IgG1 Mild monoclonal antibody Neutralizing product SARS-CoV-2 severe disease Shenzhen the spike protein Treatment university USA [DOI] 10.1007/s40265-022-01759-3 PMC 바로가기
How the COVID-19 pandemic influences the prevalence of pressure injuries in the Czech Republic: A nationwide analysis of a health registry in 2020Article Published on 2022-08-012023-07-09 Journal: Journal of tissue viability [Category] COVID19(2023년), [키워드] COVID-19 Epidemiology Hospitalization inpatient care Pressure injuries Prevalence [DOI] 10.1016/j.jtv.2022.06.003 PMC 바로가기
Inactivated vaccines prevent severe COVID-19 in patients infected with the Delta variant: A comparative study of the Delta and Alpha variants from China비활성화된 백신은 Delta 변이에 감염된 환자에서 심각한 COVID-19를 예방합니다: 중국의 Delta 및 Alpha 변이에 대한 비교 연구Article Published on 2022-08-012022-09-11 Journal: Journal of medical virology [Category] COVID19(2023년), SARS, 변종, [키워드] addition Alpha variant Antibiotics China Clinical characteristics clinical manifestation clinical manifestations Delta delta variant diagnosed disease dose Efficacy follow-up period generally mild glucocorticoid Glucocorticoids Hospital stay Hospitalization hospitalized patient Inactivated vaccine Inactivated Vaccines Infection information majority Mild MOST outcome Patient Prevent proportion replaced SARS-CoV-2 SARS-COV-2 infection severe COVID-19 vaccination Vaccine widespread Zhejiang [DOI] 10.1002/jmv.27759 PMC 바로가기 [Article Type] Article
Virologic Efficacy of Casirivimab and Imdevimab COVID-19 Antibody Combination in Outpatients With SARS-CoV-2 Infection: A Phase 2 Dose-Ranging Randomized Clinical TrialSARS-CoV-2 감염 외래 환자에서 Casirivimab과 Imdevimab COVID-19 항체 조합의 바이러스학적 효능: 2상 용량 범위 무작위 임상 시험Clinical Trial Published on 2022-08-012022-09-12 Journal: JAMA Network Open [Category] SARS, 임상, 진단, [키워드] 95% CI Administered age Asymptomatic average baseline Casirivimab clinical collected COVID-19 death dose double-blind Efficacy efficacy analysis greater Hispanic Hospitalization hypersensitivity reactions Imdevimab in viral intravenous mean difference monoclonal antibody combination outcome Outpatient parallel-group participant Participants Patient patients Phase 2 Phase 3 Placebo placebo-controlled primary end point Randomized randomized clinical trial ranged Reactions reduced reduction reported risk factor SARS-CoV-2 SARS-COV-2 infection Serious Adverse Event seronegative severe COVID-19 study drug Subcutaneous symptomatic symptomatic patient The United States Treatment Viral load were excluded white [DOI] 10.1001/jamanetworkopen.2022.25411 PMC 바로가기 [Article Type] Clinical Trial
Assessment of thromboembolism risk in COVID-19 patients with cardiovascular disease risk factors: Analysis of a Japanese Nationwide RegistryResearch article Published on 2022-08-012022-10-05 Journal: Thrombosis research [Category] COVID19(2023년), SARS, 바이오마커, [키워드] abnormality Accuracy Acute kidney injury acute respiratory distress syndrome adjusted Admission AKIAcute Kidney Injury Analysis ARDSacute respiratory distress syndrome area under the curve assessment AUCarea under the curve BNPbrain natriuretic peptide brain natriuretic peptide C-reactive protein cardiovascular disease cardiovascular disease risk factor chest X-ray Coagulation coefficient cohort study confidence interval coronavirus disease-2019 COVID-19 patient COVID-19coronavirus disease-2019 CRPC-reactive protein CVDRFcardiovascular disease risk factor D-dimer D-dimer level Deep vein thrombosis develop DVTdeep vein thrombosis embolic event Factor Hospitalization hospitalized patient identify In-hospital in-hospital mortality Invasive mechanical ventilation Japanese lactate dehydrogenase LASSOleast absolute shrinkage and selection operator LDHlactate dehydrogenase least absolute shrinkage and selection operator limitation Male sex N-terminal prohormone of brain natriuretic peptide NT-pro-BNPN-terminal prohormone of brain natriuretic peptide Occurrence operator parameter Patient patients with COVID-19 potential risk Predictive Predictive model PTEpulmonary thromboembolism Pulmonary thromboembolism receiver operating characteristic reducing Registered registry reported Result risk risk factor ROCreceiver operating characteristic shown significantly Support the primary endpoint thromboembolic Thromboembolic events Thromboembolism Venous Thromboembolism VTEVenous Thromboembolism was performed WBCWhite blood cell White blood cell with COVID-19 [DOI] 10.1016/j.thromres.2022.06.007 [Article Type] Research article